Michele Hu

Has grant

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

EPND: European Platform for Neurodegenerative Diseases

Open Date: 2021-10-01

Close Date: 2026-09-01

Grant: Close

UPP: Understanding Parkinson’s Progression

Open Date: 2021-08-01

Close Date: 2026-02-01

Grant: Close

“Developing trial-ready wearable technology for Parkinson’s disease modification”

Open Date: 2020-02-01

Close Date: 2023-04-01

Grant: Close

Artificial Intelligence for the discovery of new therapies in Parkinson’s

Open Date: 2020-02-01

Close Date: 2023-01-01

Grant: Close

ParkAI: A mobile app with machine learning analysis for measuring and predicting clinical change in Parkinson’s

Open Date: 2020-01-01

Close Date: 2021-01-01

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Stefanie Jost

Head of Neuropsychology section

University Hospital Bonn

GERMANY

View details

Cheng Jiang

University of Oxford

UNITED KINGDOM

View details

Richard Brown

King’s College London

UNITED KINGDOM

View details

Siddharth Arora

University of Oxford

UNITED KINGDOM

View details

George Tofaris

University of Oxford

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michele Hu

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease

Altered network stability in progressive supranuclear palsy

Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Quantifying activities of daily living impairment in Parkinson’s disease using the Functional Activities Questionnaire

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Validation of α-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.

Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS.

Olfactory Testing in Parkinson Disease and REM Behavior Disorder: A Machine Learning Approach.

Proof of concept: Screening for REM sleep behaviour disorder with a minimal set of sensors.

Collaborators (5)

Stefanie Jost

Cheng Jiang

Richard Brown

Siddharth Arora

George Tofaris

Make your next move.